Results 21 to 30 of about 73,607 (303)
Hematology/Oncology and Stem Cell Therapy, 2022 Objective/Background: Recurrent somatic mutations in the JAK2, calreticulin (CALR), and the MPL genes are described as drivers of BCR-ABL1-negative myeloproliferative neoplasms (MPN) that includes polycythemia vera (PV), essential thrombocytosis (ET ...
Madhavi Maddali +14 more
doaj +1 more source
Effect of leptin on the growth and expression of STAT3 in yak mammary epithelial cells [PDF]
Veterinary World, 2022 Background and Aim: Leptin (LEP) is an autocrine and paracrine factor produced by the fat pad and acinar epithelial cells of the breast. This study aimed to investigate the effects of LEP on yak mammary epithelial cells (YMECs) and the expression of ...
Baoxia Dong +6 more
doaj +1 more source
JAK2 Inhibitors: Are They the Solution? [PDF]
Clinical Lymphoma Myeloma and Leukemia, 2011 The discovery of the JAK2V617F mutation in patients with Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN) started the era of targeted therapy for these diseases. Until now, patients had few treatment options available, which usually were restricted to hydroxyurea, interferon preparations, and chemotherapy in more aggressive cases ...
Fabio P S, Santos, Srdan, Verstovsek
openaire +2 more sources
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents
Biomedical Papers, 2021 Myeloproliferative neoplasms (MPN), are clonal hematopoietic stem cell (HSC) disorders driven by gain-of-function mutations in JAK2 (JAK2-V617F), CALR or MPL genes.
Jan Stetka, Radek C. Skoda
doaj +1 more source
Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways [PDF]
Терапевтический архив, 2020 Issue.The study of activating mutations (NRAS,KRAS,FLT3,JAK2,CRLF2genes) of RAS/RAF/MEK/ERK and JAK/STAT signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) in adult patients which are included in Russian multicenter clinical trials ...
K. I. Zarubina +13 more
doaj +1 more source
Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera [PDF]
Терапевтический архив, 2016 Aim. To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Subjects and methods. A total of 61 patients (41 with ET and 20 with PV) were examined.
M A Sokolova +12 more
doaj +1 more source
JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients
Hematology/Oncology and Stem Cell Therapy, 2023 Background: Mutations in JAK2/STAT5 proliferation pathway genes are key in the diagnosis of myeloproliferative neoplasms (MPNBCR/ABLneg), with JAK2V617F being found in 50-97% of MPNBCR/ABLneg subtypes.
Karen L. Shires +4 more
doaj +1 more source
Case Reports in Oncology, 2019 Myelofibrosis (MF) can occur due to a wide variety of causes including malignant lymphoma. We report a case of splenic marginal zone lymphoma complicated by MF mimicking primary myelofibrosis (PMF).
Miyuki Tsutsui +3 more
doaj +1 more source
Studies of JAK2 mutations in myeloproliferative disorders [PDF]
, 2008 Myeloproliferative disorders (MPD) are diseases characterized by clonal hematopoiesis with overprodution of mature cells from erythroid, megakaryocytic and myeloid lineages.
Li, Sai
core +1 more source
, 2021 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm (MPN) that harbors the Philadelphia chromosomal translocation resulting in the uncontrolled production of mature granulocytes. Commonly, patients are diagnosed with CML during blood work for
Elrazi Awadelkarim Hamid Ali (16444596) +2 more
core +1 more source